Systematic approach to develop and validate  High Performance Liquid Chromatographic method  for efavirenz and its degradants

Sudhir Kumar Sahoo; Prasanta Kumar Choudhury; P N Murthy; Uma Shankar  Mishra; Saroj Kanta  Bisoyi; Lokesh  Kumar

doi:10.69857/joapr.v12i3.586

Authors

Sudhir Kumar Sahoo Royal College of Pharmacy and Health Sciences, Berhampur-760002, Orissa, India
Prasanta Kumar Choudhury Royal College of Pharmacy and Health Sciences, Berhampur-760002, Orissa, India
P N Murthy Royal College of Pharmacy and Health Sciences, Berhampur-760002, Orissa, India
Uma Shankar Mishra Royal College of Pharmacy and Health Sciences, Berhampur-760002, Orissa, India
Saroj Kanta Bisoyi Royal College of Pharmacy and Health Sciences, Berhampur-760002, Orissa, India
Lokesh Kumar Shri Shankaracharya Institute of Pharmaceutical Sciences and Research, Bhilai, CG, India

DOI:

https://doi.org/10.69857/joapr.v12i3.586

Keywords:

Efavirenz, NNRTIs, SIAMs, Purposeful Degradation, ICH Guidelines, RP-HPLC Method, Stress Testing

Abstract

Background: The crucial aspect to consider during method development and validation, ensuring accurate, precise, and specific estimation of drug substances and drug products, is stability. Various factors, including environmental, instrumental, reagent, and human factors, can pose challenges in achieving suitable method development and validation. Objective: This work aimed to develop and validate a low flow rate, LCMS compatible, simple, and rapid reverse-phase high-performance liquid chromatographic method for estimating efavirenz and its degradation products at different stress conditions. Materials and Methods: The HPLC system employed a Phenomenex Luna 5μ C18 (2) 100A (250 x 4.6 mm) column and a mobile phase of methanol: 20 millimolar ammonium formate solution (90:10) adjusted to pH 4 with formic acid. All analytes were separated within 15 minutes and detected at 247 nm. Method validation was carried out according to ICH guidelines, including linearity, accuracy, precision, ruggedness, robustness, LOD, and LOQ. Results and Discussion: The method was linear in the 10-90 μg/ml range, with a regression coefficient 0.999. Intra- and inter-day precisions, ruggedness, and robustness were within acceptable limits (≤2% RSD) with LOD and LOQ of 0.35 and 1.16 μg/ml, respectively. Degradation study indicates well resolution of the drug and degradants. Conclusion: Purposeful degradation of efavirenz resulted in different degradation products under various stress conditions, and the method demonstrated satisfactory resolution from its degradants.

Downloads

Download data is not yet available.

References

ICH guidelines. ICH Q14: Analytical Procedure Development. (2022)

Center for Biologics Evaluation and Research, Center for Drug Evaluation and Research USFDA. Q2(R1) Validation of Analytical Procedures: Text and Methodology Guidance for Industry Guidance for Industry. (2021)

Costa B, Vale N. Efavirenz: History, Development and Future. Biomolecules, 13(88), 1-11 (2023)

Pasternak AO, Vroom J, Kootstra NA, Wit FW, de Bruin M, De Francesco D, Bakker M, Sabin CA, Winston A, Prins JM, Reiss P, Berkhout B. Non-nucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy is associated with lower cell-associated HIV RNA and DNA levels compared to protease inhibitor-based therapy. Elife, 10, e68174 (2021)

Mengistu EF, Malik T, Molla MD, Adugna A, Jemal M. Liver function tests, CD4+ counts, and viral load among people living with HIV on dolutegravir compared to efavirenz-based cART; a comparative cross-sectional study. Heliyon, 10, e33054 (2024)

Scarsi KK, Smeaton LM, Podany AT, Olefsky M, Woolley E, Barr E, Pham M, Mawlana S, Supparatpinyo K, Gatechompol S, Jalil EM, Gadama L, Badal-Faesen S, Belaunzaran-Zamudio PF, Godfreyl C, Cohn SE, Mngqibisa R. Pharmacokinetics of dose-adjusted levonorgestrel emergency contraception combined with efavirenz-based antiretroviral therapy or rifampicin-containing tuberculosis regimens. Contraception, 121, 109951, 1-8 (2023)

Ambhore JP, Chaudhari SR, Cheke RS, Kharkar PS. A Concise Analytical Profile of Efavirenz: Analytical Methodologies. Crit Rev Anal Chem, 52, 1583-92 (2022).

Gurumukhi VC, Bari SB. Quantification and Validation of Stability-Indicating RP-HPLC Method for Efavirenz in Bulk and Tablet Dosage Form using Quality by Design (QbD): A Shifting Paradigm. Journal of Chromatographic Science, 60(2), 143–156 (2022)

Konidala SK, Samineni R, Rao YV, Chimakurthy J, Kolakaluri CS, Korrapati V. Novel RP-UPLC Method Development and Validation for Simultaneous Quantification of Emtricitabine, Tenofovir and Efavirenz in Bulk and Tablet Dosage Forms. Research Journal of Pharmacy and Technology, 15(7), 3141-6 (2022)

Saha P, Pandey MM. Design of Experiment (DoE)-Approach Based RP-HPLC Analytical Method Development and Validation for Estimation of Efavirenz in Bulk and Formulations. Journal of Chromatographic Science, 60(1), 35-44 (2022)

Godela R, Kammari V, Gummadi S, et al. Concurrent estimation of lamivudine, tenofovir disoproxil fumarate, and efavirenz in blended mixture and triple combination tablet formulation by a new stability indicating RP-HPLC method. Future Journal of Pharmaceutical Sciences, 7(94), 1-12 (2021)

Dessai P, Kapupara P. Development of Stability indicating RP-HPLC Method Development and Validation for the Estimation of Lamivudine and Zidovudine in Combined dosage form. Research Journal of Pharmacy and Technology, 13(10), 4909-4915 (2020)

Krishna MVVNM, Rao SV, Venugopal NVS. Forced Degradation Study for Tenofovir DF, Lamivudine and Efavirenz in Triple Combination Anti-Retroviral Tablets and Development of Validated Stability Indicating Assay Method by UPLC. Current Pharmaceutical Analysis, 15(1), 82-94 (2019)

Duarte ML, Silva AMB, da Silva JWV, Santana DP, de Castro WV, de Alencar LCA, Bedor DCG, Leal LB. Quantification of four antiretrovirals in dried blood spot and plasma using LC-MS/MS: Application to efavirenz therapeutic drug monitoring in pregnant patients. Clinical Biochemistry, 127-128, 110765 (2024)

Kim JB, Kim SJ, So M, Kim DK, Noh HR, Kim BJ, Choi YR, Kim D, Koo H, Kim T, Woo HG, Park SM. Artificial intelligence-driven drug repositioning uncovers efavirenz as a modulator of α-synuclein propagation: Implications in Parkinson's disease. Biomedicine & Pharmacotherapy, 174, 1-14 (2024)

Shelke M, Godge R, Sahane T, Pawar O, Kasar S. Stability indicating RP-HPLC method for estimation of cariprazine hydrochloride in human plasma. Journal of Applied Pharmaceutical Research, 12 (2), 27-34 (2024)

Mandhare S, Godge R, Vikhe A, Talole S. Development and validation of a QbD-based RP-HPLC method for vericiguat quantification. Journal of Applied Pharmaceutical Research, 12(2), 57-67 (2024)

Campbell JM, Colombo S, Doyle JL, Filoti DI, Hubner G, Magnenat L, Nowinski AK, Pavon JA, Singh SM, Vo LR, Woods JM, Stokes ESE. An Industry Perspective on the use of Forced Degradation Studies to Assess Comparability of Biopharmaceuticals. Journal of Pharmaceutical Sciences, 113, 505−512 (2024)

Mullani AK, Nargatti PI. Forced degradation study - a new approach for stress testing of drug substances and drug products. International Journal of Pharmaceutical Sciences and Research, 12(5), 2683-2691 (2021)

Dhiman V, Balhara A, Singh S, Tiwari S, Gananadhamu S, Talluri MVN. Characterization of stress degradation products of nintedanib by UPLC, UHPLC-Q-TOF/MS/MS and NMR: Evidence of a degradation product with a structure alert for mutagenicity. Journal of Pharmaceutical and Biomedical Analysis, 199, 1-11 (2021)